bf/NASDAQ:SMMT_icon.jpeg

NASDAQ:SMMT

Summit Therapeutics Inc.

  • Stock

24.67

+2.28%

−4.65

USD last updated 05/08 01:57:14

Last Close

29.32

04/08 22:33

Market Cap

5.82B

Beta: −1.02

Volume Today

3.01M

Avg: 2.06M

PE Ratio

−1.63

PFCF: −51.96

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase II...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -1.2-1-0.8-0.6-0.4-0.22019-06-122020-06-032021-08-112023-05-112024-08-07

    Revenue (Estimate*)

    5M10M15M20M2019-06-122020-06-032021-08-112023-05-112024-08-07

    *Estimate based on analyst consensus